Peak Bio, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PKBO research report →
Companypeak-bio.com
Peak Bio, Inc. , a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients.
- CEO
- Hoyoung Huh
- IPO
- 2021
- Employees
- 6
- HQ
- Palo Alto, CA, US
Price Chart
Valuation
- Market Cap
- $520.31K
- P/E
- -1.91
- P/S
- 0.00
- P/B
- 0.35
- EV/EBITDA
- -546.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -18.32%
- ROIC
- -16.97%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-1,676.22 · -33.11%
- EPS
- $-0.02 · -44944.94%
- Op Income
- $-1,673.558
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.02
- 52W Low
- $0.02
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 1.78
- Avg Volume
- 0
Get TickerSpark's AI analysis on PKBO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 7, 24 | SBI INVESTMENT KOREA CO., LTD. | other | 83,800 |
| Nov 14, 24 | SBI INVESTMENT KOREA CO., LTD. | sell | 3,621,489 |
| Nov 14, 24 | Patel Sandip I | other | 763,316 |
| Nov 14, 24 | Patel Sandip I | sell | 400,000 |
| Nov 14, 24 | Patel Sandip I | sell | 47,364 |
| Nov 14, 24 | Patel Sandip I | other | 0 |
| Nov 14, 24 | Neal James R | other | 37,850 |
| Nov 14, 24 | Neal James R | other | 0 |
| Nov 14, 24 | Neal James R | sell | 37,850 |
| Nov 14, 24 | Neal James R | sell | 33,340 |
Our PKBO Coverage
We haven't published any research on PKBO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PKBO Report →